CONFERENCE PROCEEDINGS
Advanced Search
Home > Proceedings > Volume PC12146 > Article
Presentation
24 May 2022 No differences in retinal fluorescence between Alzheimer’s disease patients and controls after oral curcumin in an amyloid proven cohort
Benjamin Lochocki, Jurre den Haan, Frederique J. Hart, Maurice A.G.M. Kroon, E. Marleen Kemper, Charlotte E. Teunissen, Bart van Berckel, Aleid van de Kreeke, Philip Scheltens, Jeroen J.M. Hoozemans, Frank D. Verbraak, Femke H. Bouwman, Johannes F. de Boer
Author Affiliations +
Proceedings Volume PC12146, Clinical Biophotonics II; PC121460K (2022) https://doi.org/10.1117/12.2632179
Event: SPIE Photonics Europe, 2022, Strasbourg, France
Abstract
The retina might be a promising target to identify early alterations associated with Alzheimer’s Disease (AD). Recent publications show promising results in the detection of retinal amyloid in AD patients in-vivo as well in post-mortem retinal tissue. The aim of this study is to confirm previously published findings using fluorescent retinal imaging and curcumin as labelling fluorophore. In total, 40 patients were enrolled (26 AD, 14 controls) and the subjects’ amyloid assessment was based on CSF analysis and/or amyloid PET. We administered three different curcumin formulations: Longvida, Theracurmin and Novasol. Blue fluorescence (λ = 486 nm) retinal baseline and follow-up images of 2 to 6 retinal regions were performed. The resulting images were visually assessed in a multidisciplinary setting and a selection of images were quantitatively analyzed (only from participants receiving Longvida and Novasol). The visual analysis of baseline images showed no increased fluorescence in AD patients compared to controls. Furthermore, no difference was found comparing pre- and post-curcumin images within AD and control patients. The quantitatively analysis confirmed the visual analysis, identifying similar amount of fluorescence spots in AD and control patients, even after curcumin intake. Despite previous studies assessing retinal amyloid in AD patients with fluorescent retinal imaging using curcumin, we could not confirm the retinal changes described in previous studies. We were unable to reproduce the discrimination of AD patients from controls based on fluorescent retinal amyloid visualization.
Conference Presentation
© (2022) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Citation Download Citation
Benjamin Lochocki, Jurre den Haan, Frederique J. Hart, Maurice A.G.M. Kroon, E. Marleen Kemper, Charlotte E. Teunissen, Bart van Berckel, Aleid van de Kreeke, Philip Scheltens, Jeroen J.M. Hoozemans, Frank D. Verbraak, Femke H. Bouwman, and Johannes F. de Boer "No differences in retinal fluorescence between Alzheimer’s disease patients and controls after oral curcumin in an amyloid proven cohort", Proc. SPIE PC12146, Clinical Biophotonics II, PC121460K (24 May 2022); https://doi.org/10.1117/12.2632179
ACCESS THE FULL ARTICLE
ORGANIZATIONAL
Sign in with credentials provided by your organization.
INSTITUTIONAL
Select your institution to access the SPIE Digital Library.
SELECT YOUR INSTITUTION
PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
PERSONAL SIGN IN
No SPIE Account? Create one
PURCHASE THIS CONTENT
SUBSCRIBE TO DIGITAL LIBRARY
50 downloads per 1-year subscription
Members: $195
Non-members: $335 ADD TO CART
25 downloads per 1 - year subscription
Members: $145
Non-members: $250 ADD TO CART
PURCHASE SINGLE ARTICLE
Includes PDF, HTML & Video, when available
Members: $17.00
Non-members: $21.00 ADD TO CART
PROCEEDINGS
 PRESENTATION
WATCH
PRESENTATION SAVE TO MY LIBRARY
GET CITATION
Advertisement
Advertisement
KEYWORDS
Control systems
Luminescence
Alzheimer's disease
Magnesium
Plasma
Visual analytics
Visualization
RELATED CONTENT
Subscribe to Digital Library
Receive Erratum Email Alert
Back to Top